Overview
Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets. Additionally, the Company has legacy programs in allergy and viral infections, and inner ear disorders, which it intends to partner as it plans to focus exclusively on the exciting opportunities in RNA.
Meet Altamira: Fly exclusive interview with CEO Thomas Meyer
Read Article
Altamira Therapeutics Issues Spring 2022 Shareholder Letter
View PDF